SARS-CoV-2 InfectionPhase 4ERASE-LCNCT05911906
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
A Phase 4 study testing Remdesivir in people with SARS-CoV-2 Infection and COVID-19, run by University of Derby at 4 sites in United Kingdom.
Trial summary
Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- SARS-CoV-2 Infection, COVID-19
- What is being tested?
- Remdesivir
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 73 participants
- Where
- 4 sitesUnited Kingdom
- Study dates
- 8 Oct 2024to 17 Sep 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥18 years of age at the time of enrolment
- Previously confirmed or suspected SARS-CoV-2 infection
- Confirmed diagnosis of Long COVID by a Health Care Practitioner according to the *definition provided by the World Health Organisation for persistent symptoms following a confirmed SARS-CoV-2 infection.
- Willing and able to provide informed consent, complete the surveys, and complete all planned clinical assessments, and return for scheduled study visits.
- Evidence of persistent symptom profile relative to pre-COVID-19 status as derived from patient reported outcome measures.
- Lives within commutable distance of the relevant centre, at discretion of local Principal Investigator.
- WHO define Long COVID as the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation.
Who cannot join
- Treatment history of Remdesivir, molnupiravir, paxlovid and/or any other COVID-19 anti-viral medication (\<6 months).
- A diagnosis of a compromised immune system or function from a Healthcare Professional.
- Currently engaged in a physical rehabilitation programme or intervention aimed to improve Long COVID symptom profile and/or functional status.
- Recognised as a 'severe risk' of experiencing post-exertional malaise following engagement in physical tasks. Determined using the Modified De Paul Symptom Questionnaire.
- Lack of mental capacity to provide informed consent.
- Unable to understand verbal English/have a hearing impairment that prevents adequate communication.*
Show all 15Show fewer
- Participation in another clinical drugs trial within the last 6 months
- Currently pregnant, breastfeeding or attempting to get pregnant (i.e., not using effective methods of contraception).
- Currently taking medications known to have an interaction with Remdesivir (e.g., chloroquine phosphate or hydroxychloroquine) as defined by British National Formulary (BNF) information on the selection, prescribing, dispensing and administration of medicines: https://bnf.nice.org.uk/interactions/Remdesivir/
- History of serious adverse reactions to anti-viral medication and intravenous infusions
- History of Hepatic or Renal Impairment (eGFR (\<30ml/min) and LFTs ALT\>x5 ULN).
- Exeter participants only: No recent/long standing history of CT (within 3 months)/ ongoing radiotherapy treatment. Risks of accumulative burden to be discussed as part of study involvement but it is at the discretion of participants.
- Note:
- English Comprehension: Potential participants who are unable to understand verbal English will not be eligible for this study. This is due to the necessity of telephone contact which is a key aspect of this study and the unavailability of validated questionnaires in languages other than English.
- Hearing Impairment: Unfortunately, if the participant has a hearing impairment that prevents adequate communication on the telephone, they will not be able to take part in the study. This will be clearly stated in the participant information sheet.
Trial locations and contacts
4 sites in 1 country.
United Kingdom4 sites
Derbyshire Community Health Services NHS Foundation Trust
Chesterfield, S42 7JE
University of Derby
Derby, Derby, DE22 1GB
Royal Derby Hospital (UHDB)
Derby, D22 3NE
University of Exeter / Royal Devon University Healthcare NHS FT
Exeter, EX4 4PY
About this study
Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. These symptoms affect people in different ways and have been demonstrated to broadly impact physical, mental, and cognitive health. This is called Long COVID. Currently, there are no treatments available to address the issues that patients experience but anti-viral medications have been suggested as being potentially effective. This study will recruit patients that have confirmed long COVID and participants will undertake a series of tests to determine their symptoms and the impact that their condition has had on their bodily systems. The total duration of each participant's involvement is approximately 8 weeks, and this will involve 13 visits (15 visits if taking part in Exeter) at the closest study location (Derby or Exeter). Initial assessments are conducted over three separate visits and then all participants will be scheduled to receive five consecutive days of a medication that has been identified as having the potential to reduce the impact of Long COVID. Following a period of 28 days, participants will be invited to repeat the same tests that were conducted before receiving the medication so that it can be determined how well the drug has worked. In this study we are specifically collecting information to understand how feasible this medication could be to help patients improve their condition and this will help us to determine how likely this drug is able to be used within the wider Long COVID community.
The medication that will be used within this study is an existing anti-viral medication (Remdesivir). If we find patients are able to tolerate the treatment and the research tasks we will use this information to conduct a larger trial to determine how well this drug can be used to reduce the impact of Long COVID in a greater number of patients.
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Being tested
- Remdesivir
- Keywords
- Long COVID, Anti-virals, Remdesivir, Long COVID Symptoms
- Medical subject headings
- COVID-19, Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RemdesivirDrug
Also called Veklury, PRD8099279
Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.
Participants will receive a single loading dose of 200 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV over 60 minutes on day 1, followed by, on days 2 - 5, a dose of 100 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV once daily over 30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group | Experimental | Five days of Remdesivir infusion delivered by IV. Receives: Drug: Remdesivir |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
To ascertain screening and recruitment rates (overall and by different recruitment pathways).
Measured: 55 days
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Retention and dropout rate (due to the treatment and/or trial demands, overall and by centre):
Measured: 55 days
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Adherence to treatment regimen (attendance to 5 days of IMP).
Measured: 22 days
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Completeness of study assessments (CPET, Bloods and PET/CT if in Exeter).
Measured: 55 days
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Completeness of all data collection activities including baseline and +28 days after treatment.
Measured: 55 days
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Acceptability of outcome measurements (measured by completion rates).
Measured: 55 days
Secondary outcomes (6)
To identify the most clinically relevant primary outcome for the definitive study
Quality of life, functional status and symptom burden (Pre and Post Intervention Patient Reported Outcome Measures)
Measured: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Tolerance to physical stimulus: exercise tolerance and reduced post exertional symptom exacerbation following incremental exercise.
Measured: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Physiological function, physical function, cognitive function, and emotional status and/or capacity.
Measured: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Biomarker and inflammatory profiles
Measured: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Exeter patients only - Microvascular function: whole body FDG uptake using PET/CT methods.
Measured: 55 days
To determine the clinical safety and tolerance parameters of the use of Remdesivir in the treatment of patients with Long COVID.
AE/SAE/AR/SAR/SUSAR
Measured: 55 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2023
- Study start8 Oct 2024
- Primary completion17 Sep 2025
- Study completion17 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for SARS-CoV-2 InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- One study group will receive Remdesivir.
- Masking
- None (open label)
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Derby
- Sponsor type
- University, hospital or other
- Collaborators
- University of Exeter, University of Plymouth, University Hospitals of Derby and Burton NHS Foundation Trust, Aston University, Royal Devon and Exeter NHS Foundation Trust
- Responsible party
- Principal investigator, Mark Faghy, Loughborough University
- Investigators
- Victoria Allgar, PhD, Study chair, Pen CTU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05911906
- Sponsor's protocol ID
- UoD/ERASE-LC/23
- Acronym
- ERASE-LC
- Status last verified
- Feb 2026
- First submitted
- 20 Jun 2023
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The PenCTU data team will have access to the trial dataset, including identifiable participant data. Other members of the CTU and the wider study team will have restricted access to pseudo-anonymised study data. Access to the dataset will be granted to the Sponsor and host institution on request, to permit study-related monitoring, audits and inspections. Access will be overseen by the CTU data manager and trial manager. Access to the final dataset will be provided to the trial statisticians for analysis. After the trial has been reported, the anonymised individual participant data that underlie the results will be available on request from the CI and Sponsor, along with supplementary files as required (e.g., data dictionaries, blank data collection forms, analysis code, etc). Data will be shared with (or access to the data will be provided to) requestors whose proposed use of the data has been approved by the CI and Sponsor, under an appropriate data-sharing agreement.
Publications
Faghy MA, Chynoweth J, Barnett A, Skipper L, Allgar V, Neilens H, Sands KA, Lord A, Hambly H, Aspinall PJ, Rollinson C, Strain WD, Owen R, Thomas C, Grigg MJ, Kranen SH, Mokbel K, Knapp KM, Razak HA, Ashton R, Maidment I, Bewick T. An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial. Oxf Open Immunol. 2026 Sep 16;7(1):iqag014. doi: 10.1093/oxfimm/iqag014. eCollection 2026.
PubMed 42891015Skipper L, Faghy MA, Thomas C; LC PPIE Research Group; Ashton REM, Bewick T, Owen R. Patient and public involvement and engagement in Long COVID research: embedding inclusion in research. Res Involv Engagem. 2026 Jun 10;12(1):85. doi: 10.1186/s40900-026-00890-9.
PubMed 42271537Neilens H, Allgar V, Sands KA, Chynoweth J, Lord A, Aspinall PJ, Hambly H, Barnett A, Skipper L, Bewick T, Maidment I, Razak HA, Ashton R, Strain D, Knapp K, Faghy MA. An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID. Pilot Feasibility Stud. 2026 May 1;12(1):87. doi: 10.1186/s40814-026-01823-9.
PubMed 42063202
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
- ClinicalTrials.gov ID
- NCT05911906
- Acronym / sponsor ID
- ERASE-LC / UoD/ERASE-LC/23
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Keywords
- Long COVID, Anti-virals, Remdesivir, Long COVID Symptoms
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- University of DerbyUniversity, hospital or other
- Collaborators
- University of Exeter, University of Plymouth, University Hospitals of Derby and Burton NHS Foundation Trust, Aston University, Royal Devon and Exeter NHS Foundation Trust
- Study start
- 8 Oct 2024 (actual)
- Primary completion
- 17 Sep 2025 (actual)
- Study completion
- 17 Sep 2025 (actual)
- First posted
- 22 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. These symptoms affect people in different ways and have been demonstrated to broadly impact physical, mental, and cognitive health. This is called Long COVID. Currently, there are no treatments available to address the issues that patients experience but anti-viral medications have been suggested as being potentially effective. This study will recruit patients that have confirmed long COVID and participants will undertake a series of tests to determine their symptoms and the impact that their condition has had on their bodily systems. The total duration of each participant's involvement is approximately 8 weeks, and this will involve 13 visits (15 visits if taking part in Exeter) at the closest study location (Derby or Exeter). Initial assessments are conducted over three separate visits and then all participants will be scheduled to receive five consecutive days of a medication that has been identified as having the potential to reduce the impact of Long COVID. Following a period of 28 days, participants will be invited to repeat the same tests that were conducted before receiving the medication so that it can be determined how well the drug has worked. In this study we are specifically collecting information to understand how feasible this medication could be to help patients improve their condition and this will help us to determine how likely this drug is able to be used within the wider Long COVID community.
The medication that will be used within this study is an existing anti-viral medication (Remdesivir). If we find patients are able to tolerate the treatment and the research tasks we will use this information to conduct a larger trial to determine how well this drug can be used to reduce the impact of Long COVID in a greater number of patients.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- One study group will receive Remdesivir.
| Arm | Type | Receives |
|---|---|---|
| Treatment Group | Experimental | Drug: RemdesivirFive days of Remdesivir infusion delivered by IV. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- ≥18 years of age at the time of enrolment
- Previously confirmed or suspected SARS-CoV-2 infection
- Confirmed diagnosis of Long COVID by a Health Care Practitioner according to the *definition provided by the World Health Organisation for persistent symptoms following a confirmed SARS-CoV-2 infection.
- Willing and able to provide informed consent, complete the surveys, and complete all planned clinical assessments, and return for scheduled study visits.
- Evidence of persistent symptom profile relative to pre-COVID-19 status as derived from patient reported outcome measures.
Key exclusion criteria (15 listed)
- Treatment history of Remdesivir, molnupiravir, paxlovid and/or any other COVID-19 anti-viral medication (\<6 months).
- A diagnosis of a compromised immune system or function from a Healthcare Professional.
- Currently engaged in a physical rehabilitation programme or intervention aimed to improve Long COVID symptom profile and/or functional status.
- Recognised as a 'severe risk' of experiencing post-exertional malaise following engagement in physical tasks. Determined using the Modified De Paul Symptom Questionnaire.
- Lack of mental capacity to provide informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RemdesivirAlso: Veklury, PRD8099279Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. Participants will receive a single loading dose of 200 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV over 60 minutes on day 1, followed by, on days 2 - 5, a dose of 100 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV once daily over 30 minutes. | Drug | Treatment Group |
Primary outcome
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Time frame: 55 days
To ascertain screening and recruitment rates (overall and by different recruitment pathways).
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Time frame: 55 days
Retention and dropout rate (due to the treatment and/or trial demands, overall and by centre):
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Time frame: 22 days
Adherence to treatment regimen (attendance to 5 days of IMP).
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Time frame: 55 days
Completeness of study assessments (CPET, Bloods and PET/CT if in Exeter).
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Time frame: 55 days
Completeness of all data collection activities including baseline and +28 days after treatment.
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID.
Time frame: 55 days
Acceptability of outcome measurements (measured by completion rates).
6 secondary outcomes
To identify the most clinically relevant primary outcome for the definitive study
Time frame: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Time frame: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Time frame: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Time frame: 52 days
To identify the most clinically relevant primary outcome for the definitive study
Time frame: 55 days
To determine the clinical safety and tolerance parameters of the use of Remdesivir in the treatment of patients with Long COVID.
Time frame: 55 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2026.
- Derived from this study: PubMed 42891015Faghy MA, Chynoweth J, Barnett A, Skipper L, Allgar V, Neilens H, Sands KA, Lord A, Hambly H, Aspinall PJ, Rollinson C, Strain WD, Owen R, Thomas C, Grigg MJ, Kranen SH, Mokbel K, Knapp KM, Razak HA, Ashton R, Maidment I, Bewick T. An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial. Oxf Open Immunol. 2026 Sep 16;7(1):iqag014. doi: 10.1093/oxfimm/iqag014. eCollection 2026.
- Derived from this study: PubMed 42271537Skipper L, Faghy MA, Thomas C; LC PPIE Research Group; Ashton REM, Bewick T, Owen R. Patient and public involvement and engagement in Long COVID research: embedding inclusion in research. Res Involv Engagem. 2026 Jun 10;12(1):85. doi: 10.1186/s40900-026-00890-9.
- Derived from this study: PubMed 42063202Neilens H, Allgar V, Sands KA, Chynoweth J, Lord A, Aspinall PJ, Hambly H, Barnett A, Skipper L, Bewick T, Maidment I, Razak HA, Ashton R, Strain D, Knapp K, Faghy MA. An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID. Pilot Feasibility Stud. 2026 May 1;12(1):87. doi: 10.1186/s40814-026-01823-9.
- Study websiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. The PenCTU data team will have access to the trial dataset, including identifiable participant data. Other members of the CTU and the wider study team will have restricted access to pseudo-anonymised study data. Access to the dataset will be granted to the Sponsor and host institution on request, to permit study-related monitoring, audits and inspections. Access will be overseen by the CTU data manager and trial manager. Access to the final dataset will be provided to the trial statisticians for analysis. After the trial has been reported, the anonymised individual participant data that underlie the results will be available on request from the CI and Sponsor, along with supplementary files as required (e.g., data dictionaries, blank data collection forms, analysis code, etc). Data will be shared with (or access to the data will be provided to) requestors whose proposed use of the data has been approved by the CI and Sponsor, under an appropriate data-sharing agreement.
Related trials for SARS-CoV-2 Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Victoria Allgar, PhD study chair
Pen CTU
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Remdesivir in people with SARS-CoV-2 Infection and COVID-19, run by University of Derby at 4 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the feasibility of the use of Remdesivir in the treatment of patients with Long COVID. (time frame: 55 days). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05911906, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.